Red Tree Venture Capital
Venture capital
RollingLast verified 9 Nov 2026
US life science venture capital firm investing in early-stage biotech and therapeutics, with a focus on oncology, neurology, and immunology.
0 deals in the last 24 months, latest 19 Mar 2024. Taken from its own website.
Key facts
- Stages
- Seed, Series A
- Sectors
- Biotech & pharma
- Eligible countries
- Not stated
- Provider based in
- United States
- Timing
- Rolling applications
- Focus
- first-in-class or best-in-class therapeutics; oncology, neurology, and immunology; ground-breaking life science technology platforms
- How to apply
- Apply route unknown
- Source
- https://redtreevc.com/
Recent deals
No deals in our data for the last 24 months.
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
As a dedicated life science venture firm, Red Tree employs a West Coast-centric, early stage-biased investment strategy.
https://redtreevc.com/ - Sectors
We focus primarily on entrepreneurs developing first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology,…
https://redtreevc.com/ - Stages
From the seed round to our $70M Series A, they have demonstrated the type of partnership every team hopes for.
https://redtreevc.com/
Status history
- 6 Nov 2026: Rolling (first extraction)
Is something out of date?
Suggest an editTakes 10 seconds
Something else wrong? Report an error.
Work at Red Tree Venture Capital? Claim this profile to confirm what you invest in.